Handels RLH, Green C, Gustavsson A, Herring WL, Winblad B, Wimo A, Skoldunger A, Karlsson A, Anderson R, Belger M, Bruck C, Espinosa R, Hlavka J, Jutlowitz E, Lin P-J, Lopez Mendez M, Mar J, Shewmaker P, Spackman E, Tafozzoli A, Tysinger B, Jonsson L. Cost-effectiveness models for Alzheimer's disease and related dementias: IPECAD modeling workshop cross-comparison challenge. Alzheimers Dement. 2023 May;19(5):1800-20. doi: 10.1002/alz.12811

INTRODUCTION: The credibility of model-based economic evaluations of Alzheimer’s disease (AD) interventions is central to appropriate decision-making in a policy context. We report the results of the International PharmacoEconomic Collaboration on Alzheimer’s Disease (IPECAD) Modelling Workshop Challenge.

METHODS: Two common benchmark scenarios, for the hypothetical treatment of AD mild cognitive impairment (MCI) and mild dementia, were jointly developed by 29 participants. Model effectiveness outcomes were summarized, and cross-comparisons were discussed during a structured workshop.

RESULTS: A broad concordance was established. Mean 10-year restricted survival and time in MCI in control group ranged in 10 MCI models from 6.7-9.5 years and 3.4-5.6 years respectively; and in 4 mild dementia models ranged from 5.4-7.9 (survival) and 1.5-4.2 (mild dementia).

DISCUSSION: The model comparison increased our understanding of methods, data used, and disease progression. We established a collaboration framework to assess cost-effectiveness outcomes, an important step towards transparent and credible AD models.

Share on: